Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (NCT03269669)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patients must have follicular lymphoma (grade I, II or IIIa) confirmed at initial diagnosis and at relapse with identifiable fludeoxyglucose F-18 (FDG) avid disease on PET/CT; patients that have involvement with large cell lymphoma are not eligible
2. Patients must have a whole body or limited whole body PET/CT scan performed within 42 days prior to registration
3. Patients must have bone marrow biopsy performed within 42 days prior to registration
4. Patients must have an indication for therapy as determined by the treating investigator
5. All disease must be assessed and documented on the S1608 FDG-PET/CT assessment form
6. The intent is to enroll patients with follicular lymphoma (FL) relapsed within 2 years of completing their first course of chemotherapy (CHOP or bendamustine based therapy) + anti-CD20 therapy. Patient is still eligible if he/she received radiation therapy or anti-CD20 therapy prior to chemoimmunotherapy or if maintenance anti-CD20 therapy was administered after chemoimmunotherapy
7. Patients must have either failed to achieve a complete remission, or must have relapsed within 2 years after completing CHOP or bendamustine-containing chemoimmunotherapy (including an anti-CD20 monoclonal antibody), as measured from the last dose of CHOP or bendamustine; relapsed patients must not have received any intervening chemotherapy
8. Patients must have received only 1 course of chemotherapy, containing at least 3 cycles of CHOP or bendamustine; (note that no minimum dose of bendamustine is required)
9. Patients who received any anti-CD20 antibody therapy prior to CHOP or bendamustine are eligible
10. Patients who additionally received any maintenance anti-CD-20 antibody therapy or consolidative radioimmunotherapy within 2 years of the last dose of the CHOP or bendamustine therapy are eligible
11. Involved field or involved site radiation is not considered a line of therapy; examples of eligible prior treatment regimens (note this list is not all inclusive):
12. 1st line rituximab treatment followed years later by bendamustine rituximab

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (429 Sites)

• Alaska Breast Care and Surgery LLC — Anchorage, Alaska
• Alaska Oncology and Hematology LLC — Anchorage, Alaska
• Alaska Women's Cancer Care — Anchorage, Alaska
• Anchorage Oncology Centre — Anchorage, Alaska
• Katmai Oncology Group — Anchorage, Alaska
• Providence Alaska Medical Center — Anchorage, Alaska
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• Kaiser Permanente-Anaheim — Anaheim, California
• Kaiser Permanente-Deer Valley Medical Center — Antioch, California
• PCR Oncology — Arroyo Grande, California
• Sutter Auburn Faith Hospital — Auburn, California
• Kaiser Permanente-Baldwin Park — Baldwin Park, California
• Kaiser Permanente-Bellflower — Bellflower, California
• Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
• Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
• City of Hope Comprehensive Cancer Center — Duarte, California
• Kaiser Permanente Dublin — Dublin, California
• Kaiser Permanente-Fontana — Fontana, California
• Kaiser Permanente-Fremont — Fremont, California
• Kaiser Permanente-Fresno — Fresno, California
• Kaiser Permanente South Bay — Harbor City, California
• City of Hope Seacliff — Huntington Beach, California
• City of Hope at Irvine Lennar — Irvine, California
• Kaiser Permanente-Irvine — Irvine, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.